DALLAS, Jul. 31, 2015 /PRNewswire-iReach/ -- From 2001, FMD, HPAI, PRRS and Swine were respectively been included in compulsory immunity vaccines, meanwhile, China's animal vaccine industry experienced a rapid development with a CAGR of 19.2 from 2000 to 2014. Currently the market size of China's animal vaccine industry has exceeded RMB 9 billion, which mainly formed up by pig and poultry vaccines with a respectively market share of 49% and 40% in 2014. Complete report on the china animal vaccine industry spread across 142 pages is now available at http://www.reportsnreports.com/reports/406773-research-on-china-animal-vaccine-industry-2015.html.
Photo - http://photos.prnewswire.com/prnh/20150730/250289LOGO
FMD Vaccine:
Currently there are only 7 enterprises received the official approval, including one that has not yet been put into production. CAHIC accounts for the largest share of the relatively stable governmental tender vaccine. For market-oriented vaccine, products from Jinyu Group are always in the state that lags behind demand.
HPAI Vaccine:
Currently there are 9 enterprises in this segment, HPAI sales would most probably exceed RMB 2 billion in 2015. Suspension cultivation will be the most promising direction in HPAI vaccine. Liaoning Yikang Biological Corporation Limited is the leading domestic enterprise in suspension cultivation.
Place a direct purchase order of this report at http://www.reportsnreports.com/purchase.aspx?name=406773.
PRRS Vaccine:
Porcine reproductive and respiratory syndrome would most probably no longer been an option of compulsory immunity in the near future. The existing inactivated and activated vaccines are still controversial nowadays. Gene engineering vaccine may achieve the break in this segment.
PCV Vaccine:
As the largest part of conventional vaccines, PCV came into market in 2010 with high price and low market penetration rate till now. China PCV market is led by Boehringer Ingelheim. Domestic enterprises such as Jinyu Group are now successively publishing relative gene engineering vaccines.
Swine Vaccine:
The tender price continuously decreasing and will be the first to be removed from compulsory immunity lists.
Table of Contents
1. Analysis of Animal Vaccine Industry1.1 International Animal Vaccine Industry1.1.1 Market Size1.1.2 Market Structure1.1.3 Competition Pattern1.1.4 New Diseases and New Products1.2 Chinese Animal Vaccine Industry1.2.1 Market Size1.2.2 Market Structure1.2.3 Import & Export1.2.4 Profit Level1.2.5 Entry Barriers1.2.6 Competition Pattern
2. Development Environment of China Animal Vaccine Industry2.1 Policy2.1.1 Major Policies2.1.2 Compulsory Immunization Vaccine Tender System2.2 Social Environment2.2.1 Breeding Industry is Developing Steadily2.2.2 Large-scale Breeding Becomes a Trend2.2.3 Animal Epidemics Occur Frequently
3. Prospects of China Animal Vaccine Industry3.1 Overall Forecast3.2 Swine Vaccine3.2.1 Swine Fever Vaccine3.2.2 FMD Vaccine3.2.3 PRRS Vaccine3.2.4 Porcine Circovirus Vaccine3.3 Poultry Vaccine3.4 Cattle & Sheep Vaccine3.5 Pet Vaccine
4. Major Companies4.1 China Animal Husbandry Industry Co., Ltd. (CAHIC)4.1.1 Company Profile4.1.2 Revenue Structure4.1.3 Key Financial Data4.1.5 Animal Vaccine Business4.2 Inner Mongolia Jinyu Group Stock Company4.2.1 Company Profile4.2.2 Revenue Structure4.2.3 Key Financial Data4.2.4 R&D4.2.5 Animal Vaccine Business4.3 Xinjiang Tecon Animal Husbandry Bio-Technology Co., Ltd.4.3.1 Company Profile4.3.2 Revenue Structure4.3.3 Key Financial Data4.3.4 R&D4.3.5 Clients & Suppliers4.3.6 Animal Vaccine Business4.4 Ningbo TECH-BANK Co., Ltd.4.4.1 Company Profile4.4.2 Revenue Structure4.4.3 Key Financial Data4.4.4 R&D4.4.6 Animal Vaccine Business4.5 Zhejiang Shenghua Biok Biology Co., Ltd.4.5.1 Company Profile4.5.2 Revenue Structure4.5.3 Key Financial Data4.5.4 Clients4.5.6 Animal Vaccine Business4.6 Chengdu Huasun Group Inc. Ltd.4.6.1 Company Profile4.6.2 Revenue Structure4.6.3 Key Financial Data4.6.4 Clients & Suppliers4.6.5 Animal Vaccine Business4.7 Tianjin Ringpu Bio-technology Co., Ltd.4.7.1 Company Profile4.7.2 Revenue Structure4.7.3 Key Financial Data4.7.4 R&D4.7.5 Animal Vaccine Business4.8 Guangdong Dahuanong Animal Health Products Co., Ltd. (DHN)4.8.1 Company Profile4.8.2 Revenue Structure4.8.3 Key Financial Data4.8.4 R&D4.8.5 Animal Vaccine Business4.9 Liaoning Yikang Biological Corporation Limited4.9.1 Company Profile4.9.2 Revenue Structure4.9.3 Key Financial Data4.9.4 R&D4.9.5 Clients & Suppliers4.9.6 Animal Vaccine Business4.10 Wuhan Chopper Biology Co., Ltd.4.10.1 Company Profile4.10.2 Revenue Structure4.10.3 Key Financial Data4.10.4 R&D4.10.5 Clients & Suppliers4.10.6 Animal Vaccine Business4.11 Shanghai HILE Bio-Technology Co., Ltd.4.11.1 Company Profile4.11.2 Revenue Structure4.11.3 Key Financial Data4.11.4 R&D4.11.5 Clients & Suppliers4.11.6 Animal Vaccine Business
Browse more reports on PharmaceuticalsMarket at http://www.reportsnreports.com/market-research/pharmaceuticals/.
About Us:
ReportsnReports.com (http://www.reportsnreports.com/) is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries. Contact [email protected] for further information.
Media Contact: Ritesh Tiwari, ReportsnReports, + 1 888 391 5441, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE ReportsnReports
Advertisement
Photo - http://photos.prnewswire.com/prnh/20150730/250289LOGO
FMD Vaccine:
Currently there are only 7 enterprises received the official approval, including one that has not yet been put into production. CAHIC accounts for the largest share of the relatively stable governmental tender vaccine. For market-oriented vaccine, products from Jinyu Group are always in the state that lags behind demand.
Advertisement
HPAI Vaccine:
Currently there are 9 enterprises in this segment, HPAI sales would most probably exceed RMB 2 billion in 2015. Suspension cultivation will be the most promising direction in HPAI vaccine. Liaoning Yikang Biological Corporation Limited is the leading domestic enterprise in suspension cultivation.
Place a direct purchase order of this report at http://www.reportsnreports.com/purchase.aspx?name=406773.
PRRS Vaccine:
Porcine reproductive and respiratory syndrome would most probably no longer been an option of compulsory immunity in the near future. The existing inactivated and activated vaccines are still controversial nowadays. Gene engineering vaccine may achieve the break in this segment.
PCV Vaccine:
As the largest part of conventional vaccines, PCV came into market in 2010 with high price and low market penetration rate till now. China PCV market is led by Boehringer Ingelheim. Domestic enterprises such as Jinyu Group are now successively publishing relative gene engineering vaccines.
Swine Vaccine:
The tender price continuously decreasing and will be the first to be removed from compulsory immunity lists.
Table of Contents
1. Analysis of Animal Vaccine Industry1.1 International Animal Vaccine Industry1.1.1 Market Size1.1.2 Market Structure1.1.3 Competition Pattern1.1.4 New Diseases and New Products1.2 Chinese Animal Vaccine Industry1.2.1 Market Size1.2.2 Market Structure1.2.3 Import & Export1.2.4 Profit Level1.2.5 Entry Barriers1.2.6 Competition Pattern
2. Development Environment of China Animal Vaccine Industry2.1 Policy2.1.1 Major Policies2.1.2 Compulsory Immunization Vaccine Tender System2.2 Social Environment2.2.1 Breeding Industry is Developing Steadily2.2.2 Large-scale Breeding Becomes a Trend2.2.3 Animal Epidemics Occur Frequently
3. Prospects of China Animal Vaccine Industry3.1 Overall Forecast3.2 Swine Vaccine3.2.1 Swine Fever Vaccine3.2.2 FMD Vaccine3.2.3 PRRS Vaccine3.2.4 Porcine Circovirus Vaccine3.3 Poultry Vaccine3.4 Cattle & Sheep Vaccine3.5 Pet Vaccine
4. Major Companies4.1 China Animal Husbandry Industry Co., Ltd. (CAHIC)4.1.1 Company Profile4.1.2 Revenue Structure4.1.3 Key Financial Data4.1.5 Animal Vaccine Business4.2 Inner Mongolia Jinyu Group Stock Company4.2.1 Company Profile4.2.2 Revenue Structure4.2.3 Key Financial Data4.2.4 R&D4.2.5 Animal Vaccine Business4.3 Xinjiang Tecon Animal Husbandry Bio-Technology Co., Ltd.4.3.1 Company Profile4.3.2 Revenue Structure4.3.3 Key Financial Data4.3.4 R&D4.3.5 Clients & Suppliers4.3.6 Animal Vaccine Business4.4 Ningbo TECH-BANK Co., Ltd.4.4.1 Company Profile4.4.2 Revenue Structure4.4.3 Key Financial Data4.4.4 R&D4.4.6 Animal Vaccine Business4.5 Zhejiang Shenghua Biok Biology Co., Ltd.4.5.1 Company Profile4.5.2 Revenue Structure4.5.3 Key Financial Data4.5.4 Clients4.5.6 Animal Vaccine Business4.6 Chengdu Huasun Group Inc. Ltd.4.6.1 Company Profile4.6.2 Revenue Structure4.6.3 Key Financial Data4.6.4 Clients & Suppliers4.6.5 Animal Vaccine Business4.7 Tianjin Ringpu Bio-technology Co., Ltd.4.7.1 Company Profile4.7.2 Revenue Structure4.7.3 Key Financial Data4.7.4 R&D4.7.5 Animal Vaccine Business4.8 Guangdong Dahuanong Animal Health Products Co., Ltd. (DHN)4.8.1 Company Profile4.8.2 Revenue Structure4.8.3 Key Financial Data4.8.4 R&D4.8.5 Animal Vaccine Business4.9 Liaoning Yikang Biological Corporation Limited4.9.1 Company Profile4.9.2 Revenue Structure4.9.3 Key Financial Data4.9.4 R&D4.9.5 Clients & Suppliers4.9.6 Animal Vaccine Business4.10 Wuhan Chopper Biology Co., Ltd.4.10.1 Company Profile4.10.2 Revenue Structure4.10.3 Key Financial Data4.10.4 R&D4.10.5 Clients & Suppliers4.10.6 Animal Vaccine Business4.11 Shanghai HILE Bio-Technology Co., Ltd.4.11.1 Company Profile4.11.2 Revenue Structure4.11.3 Key Financial Data4.11.4 R&D4.11.5 Clients & Suppliers4.11.6 Animal Vaccine Business
Browse more reports on PharmaceuticalsMarket at http://www.reportsnreports.com/market-research/pharmaceuticals/.
About Us:
ReportsnReports.com (http://www.reportsnreports.com/) is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries. Contact [email protected] for further information.
Media Contact: Ritesh Tiwari, ReportsnReports, + 1 888 391 5441, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE ReportsnReports
